Drug intelligence / Profile preview

candesartan cilexetil + chlorthalidone + amlodipine

Development stage
Phase 3
Lead developer
Libbs Farmacêutica
Modality
Small Molecules
Administration
Oral
01

Overview

Candesartan cilexetil + chlorthalidone + amlodipine is a fixed-dose combination medication used for the treatment of hypertension. This triple therapy combines three antihypertensive agents with complementary mechanisms of action to provide comprehensive blood pressure control. Candesartan cilexetil is an angiotensin II receptor blocker (ARB) that inhibits the effects of angiotensin II, leading to vasodilation and reduced aldosterone-mediated sodium and water retention. Chlorthalidone is a thiazide-like diuretic that promotes renal excretion of sodium and water, reducing plasma volume and peripheral vascular resistance. Amlodipine is a calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, resulting in vasodilation and decreased blood pressure[1][5][8]. The combination targets multiple pathways involved in hypertension management, offering improved efficacy over monotherapy or dual therapy regimens[1][5]. It is primarily indicated for systemic arterial hypertension.

Other names
candesartan cilexetil/chlorthalidone/amlodipine besylate
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on candesartan cilexetil + chlorthalidone + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on candesartan cilexetil + chlorthalidone + amlodipine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call